Almost every controlled trial we found was run in older adults or in people with a diagnosed condition. That matters for anyone reading this page as a healthy adult: as of November 11, 2026 we found no randomized placebo-controlled trials of acetyl-L-carnitine on cognition, mood or fatigue in healthy adults (PubMed and Europe PMC search, November 11, 2026). The one study in healthy people we found was a pilot in 17 young adults aged 22 to 27, with an untreated control group for only one test [17].
Does acetyl-L-carnitine improve memory and cognitive function?
Evidence is mixed, and all of it comes from people with mild cognitive impairment or Alzheimer's disease, a clinical population; results may not apply to healthy adults.
The more favorable synthesis is a 2003 meta-analysis (a study that pools the results of several trials) of double-blind, placebo-controlled trials lasting at least 3 months in people with mild cognitive impairment or mild Alzheimer's disease [1]. Compared with placebo, acetyl-L-carnitine showed a small advantage on an integrated summary of clinical and psychometric tests (effect size 0.201, 95% confidence interval 0.107-0.295) [1]. Its funding is not stated in the PubMed record, and the abstract does not give the number of trials or participants [1].
The Cochrane review published the same year reached a more cautious reading. It included 11 trials, all limited to people with Alzheimer's disease [2]. It found a benefit on one measure, the number of people rated as improved on the clinician's global impression at 12 and 24 weeks (but not at 52 weeks), and no evidence of benefit on cognition, severity of dementia, daily function, or the global impression scored as a continuous measure [2]. The reviewers warned that, given the large number of comparisons made, the significant result may be due to chance [2].
The two largest individual trials point the same way as the Cochrane review. In a 1-year trial, 431 patients aged 50 or older with mild to moderate Alzheimer's disease took 3 g a day or placebo, and both groups declined at the same rate on all primary and most secondary measures [3]. A follow-up 1-year trial of 229 patients aged 45 to 65 with early-onset Alzheimer's disease found that acetyl-L-carnitine failed to slow decline [4]. Funding is not stated in the PubMed records of either trial, and two of the four authors of the 2000 trial listed the drug company Sigma-Tau Pharmaceuticals as their affiliation (Crossref record of the article) [4].
The two reviews differ in who they included (the meta-analysis added people with mild cognitive impairment) and in how outcomes were combined, and the Cochrane authors note that earlier and later trials used very different methods [1][2]. The more conservative reading is the Cochrane one.
For healthy adults, the only data we have is from the pilot study in 17 young adults who received 1.5 g/day for 1 month (not randomized or placebo controlled) [17]. This pilot cannot show effects in healthy people. For a broader overview, see our pages on memory and healthy brain aging.
Does acetyl-L-carnitine reduce mental fatigue?
Two controlled trials in clinical or older groups reported lower mental-fatigue scores, but the evidence base is small, comes from one research team, and relies on questionnaire scores; results may not apply to healthy adults.
In a trial of 96 adults over 70 (age range 71-88) who met criteria for chronic fatigue, indexed in PubMed as a randomized controlled trial, mental-fatigue scores fell by 3.3 points with acetyl-L-carnitine against a rise of 0.6 in the comparison group [9]. The abstract does not describe the comparison group, the dose or the duration [9].
In 121 patients with cirrhosis and overt hepatic encephalopathy (a brain complication of liver disease, a clinical population), 2 g taken twice a day for 90 days improved mental-fatigue scores in the milder group compared with placebo (-1.7 compared with -0.3) [11]. A trial in 92 prefrail older adults, using 1.5 g twice a day for 3 months, reported increases in Mini-Mental State Examination score and walking distance compared with placebo [10]. Its abstract calls the study both randomized and observational, which leaves its design unclear [10].
All three trials share an author and research team (Malaguarnera M is an author on each) [9][10][11]. A 2019 Cochrane review of that team's five trials in liver disease, with 398 participants, noted that all were conducted in Italy by a single team, all were at high risk of bias and underpowered, and all of the evidence was very low quality [12]. Its fatigue data came from a single trial, the 121-patient trial above; the review judged the effects uncertain and the evidence very low quality [12]. The Cochrane authors also noted that none of those trials was sponsored by the pharmaceutical industry [12].
As noted at the start of this section, we found no placebo-controlled fatigue trials in healthy adults. Our mental energy and fatigue page covers compounds with trials in healthy people.
Does acetyl-L-carnitine affect mood?
Meta-analyses report fewer depressive symptoms than placebo, but only in clinical populations, mostly people with diagnosed mood disorders, and the pooled results vary widely between trials; results may not apply to healthy adults.
A 2018 meta-analysis included 12 randomized controlled trials with 791 participants (mean age 54 years, 65% female) [6]. Pooling nine trials in these mostly clinical populations, acetyl-L-carnitine reduced depressive symptoms compared with placebo or no intervention (standardized mean difference -1.10, 95% CI -1.65 to -0.56) [6]. Heterogeneity was high (I-squared 86%), meaning the trials disagreed a good deal about the size of the effect [6]. In three trials in the same kind of population that compared it with established antidepressants, symptom changes were similar and adverse effects were less frequent with acetyl-L-carnitine [6]. Those comparisons involved people with diagnosed depressive disorders; they do not show that it can stand in for prescribed medicine [6]. Subgroup analyses suggested the largest effect in older adults, and the authors called for large trials to confirm or refute the findings [6].
A 2026 synthesis of 15 studies (14 randomized trials and one open-label study) with 809 participants with major depressive or bipolar disorder reached a similar conclusion against placebo and also called for larger, longer studies [7]. Several of its authors list industry advisory roles or grants in the paper's conflict-of-interest statement, some described as outside the submitted work [7].
Among the individual trials, a 7-week double-blind study in 80 older adults with diagnosed dysthymic disorder (long-lasting low mood) found results equivalent to a prescription antidepressant; it had no placebo arm [8]. For the wider mood evidence, see our mood and stress page.
What the evidence does not show
The trials summarized here do not show effects in healthy adults on memory, attention, mental fatigue or mood (see the dated search note at the start of this section).
They also do not show that it slows decline in Alzheimer's disease; a post hoc age pattern in the earlier 1-year trial was not confirmed by the later trial designed to test it [3][4].